A novel oral formulation of BIO 300 confers prophylactic radioprotection from acute radiation syndrome in mice

References

• Calveley VL, Jelveh S, Langan A, Mahmood J, Yeung IW, Van Dyk J, Hill RP. 2010. Genistein can mitigate the effect of radiation on rat lung tissue. Radiat Res. 173(5):602–611.
   PubMed Web of Science ®Google Scholar
• Cheema AK, Mehta KY, Santiago PT, Fatanmi OO, Kaytor MD, Singh VK. 2019. Pharmacokinetic and metabolomic studies with BIO 300, a nanosuspension of genistein, in a nonhuman primate model. Int J Mol Sci. 20(5):1231.
   Web of Science ®Google Scholar
• Clayton NP, Khan-Malek RC, Dangler CA, Zhang D, Ascah A, Gains M, Gardner B, Mockbee C, Keutzer JM, McManus J, et al. 2021. Sargramostim (rhu GM-CSF) improves survival of non-human primates with severe bone marrow suppression after acute, high-dose, whole-body irradiation. Radiat Res. 195(2):191–199.
   PubMed Web of Science ®Google Scholar
• Deviatkina TA, Brechko VV, Tarasenko LM, Zviago'lskaia IN, Bezuglyĭ IV, Rituma IR, Klusha VE. 1989. Correction of lipid peroxidation in stress with the peptide bioregulator thymopentin. Fiziol Zh. 35(5):14–18.
   PubMedGoogle Scholar
• DiCarlo AL, Homer MJ, Coleman CN. 2021. United States medical preparedness for nuclear and radiological emergencies. J Radiol Prot.
   Google Scholar
• DiCarlo AL, Jackson IL, Shah JR, Czarniecki CW, Maidment BW, Williams JP. 2012. Development and licensure of medical countermeasures to treat lung damage resulting from a radiological or nuclear incident. Radiat Res. 177(5):717–721.
   PubMed Web of Science ®Google Scholar
• DiCarlo AL, Maher C, Hick JL, Hanfling D, Dainiak N, Chao N, Bader JL, Coleman CN, Weinstock DM. 2011. Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation. Disaster Med Public Health Prep. 5(Suppl. 1):S32–S44.
   PubMed Web of Science ®Google Scholar
• Farese AM, Cohen MV, Katz BP, Smith CP, Gibbs A, Cohen DM, MacVittie TJ. 2013. Filgrastim improves survival in lethally irradiated nonhuman primates. Radiat Res. 179(1):89–100.
   PubMed Web of Science ®Google Scholar
• Farese AM, MacVittie TJ. 2015. Filgrastim for the treatment of hematopoietic acute radiation syndrome. Drugs Today. 51(9):537–548.
   PubMed Web of Science ®Google Scholar
• Gale RP, Armitage JO. 2018. Are we prepared for nuclear terrorism? N Engl J Med. 378(13):1246–1254.
   PubMed Web of Science ®Google Scholar
• Gale RP, Armitage JO. 2021. Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations. Blood Rev. 45:100690.
   PubMed Web of Science ®Google Scholar
• Gale RP, Armitage JO, Hashmi SK. 2021. Emergency response to radiological and nuclear accidents and incidents. Br J Haematol. 192(6):968–972.
   PubMed Web of Science ®Google Scholar
• Garofalo M, Bennett A, Farese AM, Harper J, Ward A, Taylor-Howell C, Cui W, Gibbs A, Lasio G, Jackson W 3rd, et al. 2014. The delayed pulmonary syndrome following acute high-dose irradiation: a rhesus macaque model. Health Phys. 106(1):56–72.
   PubMed Web of Science ®Google Scholar
• Girgis M, Li Y, Ma J, Sanda M, Wise SY, Fatanmi OO, Kaytor MD, Cheema AK, Singh VK. 2020. Comparative proteomic analysis of serum from nonhuman primates administered BIO 300: a promising radiation countermeasure. Sci Rep. 10(1):19343.
   PubMed Web of Science ®Google Scholar
• Gluzman-Poltorak Z, Vainstein V, Basile LA. 2014. Recombinant interleukin-12, but not granulocyte-colony stimulating factor, improves survival in lethally irradiated nonhuman primates in the absence of supportive care: evidence for the development of a frontline radiation medical countermeasure. Am J Hematol. 89(9):868–873.
   PubMed Web of Science ®Google Scholar
• Ha CT, Li XH, Fu D, Xiao M, Landauer MR. 2013. Genistein nanoparticles protect mouse hematopoietic system and prevent proinflammatory factors after gamma irradiation. Radiat Res. 180(3):316–325.
   PubMed Web of Science ®Google Scholar
• Hall EJ, Giaccia AJ. 2012. Radiobiology for the radiobiologist. Philadelphia (PA): Lippincott Williams and Wilkins.
   Google Scholar
• Hanedan Uslu G, Canyilmaz E, Serdar L, Ersöz Ş. 2018. Protective effects of genistein and melatonin on mouse liver injury induced by whole-body ionising radiation. Mol Clin Oncol. 10:261–266.
   PubMed Web of Science ®Google Scholar
• Hankey KG, Farese AM, Blaauw EC, Gibbs AM, Smith CP, Katz BP, Tong Y, Prado KL, MacVittie TJ. 2015. Pegfilgrastim improves survival of lethally irradiated nonhuman primates. Radiat Res. 183(6):643–655.
   PubMed Web of Science ®Google Scholar
• Heylmann D, Ponath V, Kindler T, Kaina B. 2021. Comparison of DNA repair and radiosensitivity of different blood cell populations. Sci Rep. 11(1):2478.
   PubMed Web of Science ®Google Scholar
• Jackson IL, Pavlovic R, Alexander AA, Connors CQ, Newman D, Mahmood J, Eley J, Harvey AJ, Kaytor MD, Vujaskovic Z. 2019. BIO 300, a nanosuspension of genistein, mitigates radiation-induced erectile dysfunction and sensitizes human prostate cancer xenografts to radiation therapy. Int J Radiat Oncol Biol Phys. 105(2):400–409.
   PubMed Web of Science ®Google Scholar
• Jackson IL, Xu P, Hadley C, Katz BP, McGurk R, Down JD, Vujaskovic Z. 2012. A preclinical rodent model of radiation-induced lung injury for medical countermeasure screening in accordance with the FDA animal rule. Health Phys. 103(4):463–473.
   PubMed Web of Science ®Google Scholar
• Jackson IL, Zodda A, Gurung G, Pavlovic R, Kaytor MD, Kuskowski MA, Vujaskovic Z. 2017. BIO 300, a nanosuspension of genistein, mitigates pneumonitis/fibrosis following high-dose radiation exposure in the C57L/J murine model. Br J Pharmacol. 174(24):4738–4750.
   PubMed Web of Science ®Google Scholar
• Jones JW, Jackson IL, Vujaskovic Z, Kaytor MD, Kane MA. 2017. Targeted metabolomics identifies pharmacodynamic biomarkers for BIO 300 mitigation of radiation-induced lung injury. Pharm Res. 34(12):2698–2709.
   PubMed Web of Science ®Google Scholar
• Kim JS, Heo K, Yi JM, Gong EJ, Yang K, Moon C, Kim SH. 2012. Genistein mitigates radiation-induced testicular injury. Phytother Res. 26(8):1119–1125.
   PubMed Web of Science ®Google Scholar
• Landauer M. 2008. Radioprotection by the soy isoflavone genistein. In: Arora R, editor. Herbal radiomodulators: applications in medicine, homeland defense and space. Wallingford (UK): CABI Publishing.
   Google Scholar
• Landauer MR, Harvey AJ, Kaytor MD, Day RM. 2019. Mechanism and therapeutic window of a genistein nanosuspension to protect against hematopoietic-acute radiation syndrome. J Radiat Res. 60(3):308–317.
   PubMed Web of Science ®Google Scholar
• MacVittie TJ, Farese AM, Kane MA. 2019. ARS, DEARE, and multiple-organ injury: a strategic and tactical approach to link radiation effects, animal models, medical countermeasures, and biomarker development to predict clinical outcome. Health Phys. 116(4):453.
   PubMed Web of Science ®Google Scholar
• National Research Council of the National Academy of Sciences. 2011. Guide for the care and use of laboratory animals. Washington (DC): National Academies Press.
   Google Scholar
• Neta R, Oppenheim JJ, Douches SD. 1988. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor. J Immunol. 140(1):108–111.
   PubMed Web of Science ®Google Scholar
• Seed TM, Inal CE, Singh VK. 2014. Radioprotection of hematopoietic progenitors by low dose amifostine prophylaxis. Int J Radiat Biol. 90(7):594–604.
   PubMed Web of Science ®Google Scholar
• Sharma NK, Holmes-Hampton GP, Kumar VP, Biswas S, Wuddie K, Stone S, Aschenake Z, Wilkins WL, Fam CM, Cox GN, et al. 2020. Delayed effects of acute whole body lethal radiation exposure in mice pre-treated with BBT-059. Sci Rep. 10(1):6825.
   PubMed Web of Science ®Google Scholar
• Singh VK, Garcia M, Seed TM. 2017a. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status. Int J Radiat Biol. 93(9):870–884.
   PubMed Web of Science ®Google Scholar
• Singh VK, Hanlon BK, Santiago PT, Seed TM. 2017b. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with 'standard of care' medicinal and procedures not requiring regulatory approval for use. Int J Radiat Biol. 93(9):885–906.
   PubMed Web of Science ®Google Scholar
• Singh VK, Seed TM. 2017. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures. Int J Radiat Biol. 93(9):851–869.
   PubMed Web of Science ®Google Scholar
• Singh VK, Seed TM. 2018. An update on sargramostim for treatment of acute radiation syndrome. Drugs Today. 54(11):679–693.
   PubMed Web of Science ®Google Scholar
• Singh VK, Seed TM. 2020. BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure. Expert Opin Investig Drugs. 29(5):429–441.
   PubMed Web of Science ®Google Scholar
• Singh VK, Wise SY, Fatanmi OO, Scott J, Romaine PL, Newman VL, Verma A, Elliott TB, Seed TM. 2014. Progenitors mobilized by gamma-tocotrienol as an effective radiation countermeasure. PLOS One. 9(11):e114078.
   PubMed Web of Science ®Google Scholar
• Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, Dynan WS, Fike JR, Grdina DJ, Greenberger JS, et al. 2004. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3–4, 2003. Radiat Res. 162(6):711–728.
   PubMed Web of Science ®Google Scholar
• Unthank JL, Miller SJ, Quickery AK, Ferguson EL, Wang M, Sampson CH, Chua HL, DiStasi MR, Feng H, Fisher A, et al. 2015. Delayed effects of acute radiation exposure in a murine model of the H-ARS: multiple-organ injury consequent to <10 Gy total bod irradiation. Health Phys. 109:511–521.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. 2021. Animal rule approvals [Online]. U.S. Food and Drug Administration; [accessed 2021 Jun 23]. https://www.fda.gov/drugs/nda-and-bla-approvals/animal-rule-approvals.
   Google Scholar
• Wong K, Bunin DI, Bujold K, Javitz HS, Bakke J, Gahagen J, Wierzbicki W, Andreasen DA, Authier S, Chang PY. 2020a. Romiplostim (Nplate) alone and in combination with pegfilgrastim (Neulasta) increased survival and reduces incidence, duration, and severity of thrombocytopenia post-irradiation in non-human primates. Annual Conference of Radiation Research Society. Virtual.
   Google Scholar
• Wong K, Chang PY, Fielden M, Downey AM, Bunin D, Bakke J, Gahagen J, Iyer L, Doshi S, Wierzbicki W, et al. 2020b. Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates. Int J Radiat Biol. 96(1):155–166.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Pouliot M, Downey AM, Mockbee C, Roychowdhury D, Wierzbicki W, Authier S. 2020. Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model. Int J Radiat Biol.
   Google Scholar